Axsome Therapeutics Inc. ( (AXSM) ) has released its Q2 earnings. Here is a breakdown of the information Axsome Therapeutics Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for central nervous system disorders, with a portfolio that includes FDA-approved medications for depression, sleep disorders, and migraine, as well as a robust pipeline of late-stage development programs.
In its second quarter of 2025, Axsome Therapeutics reported a significant increase in net product revenue, reaching $150 million, a 72% growth year-over-year. The company highlighted the strong performance of its key products, AUVELITY and SUNOSI, and the recent launch of SYMBRAVO for migraine treatment.
AUVELITY, a treatment for major depressive disorder, achieved $119.6 million in sales, marking an 84% increase from the previous year. SUNOSI, used for excessive daytime sleepiness, also saw a 35% rise in revenue. The newly launched SYMBRAVO contributed $0.4 million in sales. Axsome is also expanding its market access and has signed its first group purchasing organization contract for SYMBRAVO.
Despite a net loss of $48 million for the quarter, the company reduced its losses compared to the previous year. Axsome’s development pipeline is progressing, with plans to submit new drug applications for AXS-05 and AXS-12 later in the year, and several clinical trials set to commence or yield results in the near future.
Looking ahead, Axsome Therapeutics remains focused on advancing its neuroscience pipeline and expanding market access for its products, with expectations of achieving cash flow positivity based on its current operating plan.